摘要
目的探讨经皮经肝选择性门静脉栓塞术(SPVE)的技术要点和安全性。方法对41例肝脏肿瘤患者(包括原发性肝癌13例,转移性肝癌28例)行SPVE,对其中32例同期行TACE术(SPVE+TACE组),9例未行或未同期行TACE术(单纯SPVE组)。术后回顾性分析SPVE的技术要点、并发症及临床安全性。结果对41例均成功完成SPVE术,成功率100%;术后第3天患者ALT、AST、TB较术前升高,SPVE+TACE组升高更为明显,至术后第7天均明显下降。5例出现SPVE相关并发症,包括2例异位门静脉栓塞、1例暂时性肝功能衰竭、1例肝包膜下出血和1例肝内门静脉-静脉瘘。结论 SPVE作为肝脏外科手术和TACE术的重要辅助技术是可行的,但术后相关并发症应引起足够重视。
Objective To discuss the main technical methods of percutaneous transhepatic selective portal vein emboliza tion （SPVE）, and to assess its security. Methods Forty-one patients （13 with primary liver carcinoma and 28 with meta static liver cancer） underwent SPVE, 32 of which simultaneously underwent TACE （SPVE＋TACE group）, while 9 of which did not undergo TACE within 1 week of SPVE （single SPVE group）. The technology of SPVE, procedure-related complications and its clinical security were retrospectively analyzed. Results SPVE was successfully performed in all 41 patients, and the success rate was 100 %. On the 3rd day after treatment, alanine aminotransferase （ALT）, aspartate ami notransferase （AST） and total bilirubin （TB） increased, in SPVE＋TACE group more obviously than in single SPVE group. However, on the 7th day after treatment, ALT, AST and TB decreased significantly. Complications caused by SPVE occurred in 5 patients, including ectopic portal embolization in 2 patients, transient liver failure, liver capsule bleed ing, and portal vein-hepatic vein fistula in 1 patient, respectively. Conclusion SPVE is an important aided technology for liver surgery and TACE. However, suHicient attention should be paid to the relevant complications caused by the opera tion.
出处
《中国医学影像技术》
CSCD
北大核心
2012年第11期2028-2032,共5页
Chinese Journal of Medical Imaging Technology
关键词
肝肿瘤
门静脉
化学栓塞
治疗性
安全性
Liver neoplasms Portal vein Chemoembolization, therapeutic Safety
